Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
At Rutgers Cancer Institute of New Jersey, scientific research goes beyond traditional microscopes and beakers. Our research members – whether basic scientists, bioinformatics specialists, statisticians, clinical specialists, population scientists, or others – have unique expertise in various translational aspects of cancer research. They work collaboratively to translate the latest innovations in cancer research into tomorrow’s treatments for cancer patients.
Current research of the White Laboratory at Rutgers Cancer Institute of New Jersey has focused on translational research modulating the apoptosis pathway for cancer therapy and on the role of autophagy and cellular metabolism in cancer progression and treatment.
Dr. Elisa V. Bandera is an epidemiologist at Rutgers Cancer Institute of New Jersey and her research and training program focuses on the role of nutritional, hormonal, and other lifestyle factors play on cancer prevention and survival. She is also interested in early determinants of breast cancer risk.
The Carpizo Laboratory studies cancer biology of gastrointestinal cancers with an emphasis on developmental therapeutics. Studies range from basic biology to provide clues for novel therapies, to translational research projects to move forward exciting new technologies for cancer treatment.
Dr. Chan’s lab is interested in understanding the role of p53 in cancer, and focuses on cancer genomics, cancer evolution and resistance to therapy, and gene regulation.
The cancer genome informatics group, headed by Dr. Subhajyoti De, develops and applies novel genomics methods and computational toolsets to understand the hallmarks of cancer, and use that knowledge for better diagnosis, stratification, and treatment of this disease.
The Drake Laboratory studies advanced prostate cancer and how new targeted therapies can be identified and tested in this disease. Using approaches from mass spectrometry to in vivo experimental models, the Drake Lab investigates how kinases can be effectively identified and targeted for personalized medicine.
The Gatza Laboratory leverages cancer genomics and bioinformatics with experimental molecular biology and genetics to identify and elucidate mechanisms of oncogenic signaling and cancer genesis as a means to further understand breast and ovarian tumor biology and to develop personalized cancer therapies.
The research interest of Dr. Hu’s laboratory is to understand the alteration of important cancer-related signaling pathways in tumorigenesis, including the p53 and LIF signaling.
The Khiabanian Laboratory develops mathematical methods and employs high-throughput genomics techniques to understand the underlying genetics of human malignancies and the molecular epidemiology of disease-causing organisms, especially to study the evolution of clonal expansions in the context of disease transformation and relapse.
Led by Dr. Hatem Sabaawy, investigators at the Cancer Institute's zebrafish laboratory use zebrafish models to map the common genetic defects in cancer, identify new small molecules for targeted treatment, and predict each cancer patient's response to therapy in precision medicine trials. Among other applications, learn how zebrafish research is helping in the fight against prostate cancer.
The Zloza laboratory focuses on understanding the interplay between infections, cancer, and the immune system.
The research at the Center for Systems and Computational Biology focuses on cancer genomics and translational medicine, particularly developing novel quantitative and experimental approaches to discover disease-driving aberrations, understand cancer pathogenesis, improve diagnosis, and design effective clinical trials and precise treatment strategies for patients under active care.